Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
21 Sep 2024
21 Sep 2024
Historique:
received:
22
01
2024
accepted:
03
09
2024
revised:
07
08
2024
medline:
22
9
2024
pubmed:
22
9
2024
entrez:
21
9
2024
Statut:
aheadofprint
Résumé
To compare visual outcomes for low vision eyes (LVE) (<35 letters LogMAR or <20/200 Snellen) versus non-low vision eyes (NLVE) (>35 letters LogMAR or >20/200 Snellen) at the time of the first injection in a clinical practice setting. Subgroup analysis of a multicenter national database of treatment- naïve eyes neovascular age related macular degeneration (nAMD) treated with anti-VEGF intravitreal injections divided into LVE and NLVE. Demographics, visual acuity (VA) at baseline and subsequent timepoints (12, 24, and 36 months), number of injections and visits data were collected using a validated web-based tool (Fight Retinal Blindness!). 3138 eyes were included, 705 LVE and 2433 NLVE. The LVE group had the greatest VA gain (p < 0.001), at 12, 24, and 36 months (+15, +15, and +13 letters respectively). The proportion of patients with VA loss (-5 letters) differed between groups at 12, 24, and 36 and was significantly greater (p < 0.001) in NLVE. The proportion of patients with VA gain (+5 letters) was significantly higher (p < 0.001) in LVE in all timeframes. The proportions of LVE that still had VA ≤ 35 letters at 12, 24, and 36 months were 54%, 54%, and 57%. Conversely, 8%, 9%, and 8% of LVE achieved VA ≥ 70 letters at 12, 24, and 36 months. LVE received fewer intravitreal injections than NLVE throughout follow-up (6, 9, 12 vs 7, 11, 15). Findings of this study support the need for ongoing therapy in patients with initial visual acuity less than 35 letters since sustained visual improvements can be achieved and maintained for the first 3 years of treatment.
Identifiants
pubmed: 39306616
doi: 10.1038/s41433-024-03322-8
pii: 10.1038/s41433-024-03322-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
Heier JS, Brown DM, Chong V, Korobelnik J, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48. https://doi.org/10.1016/j.ophtha.2012.09.006 .
doi: 10.1016/j.ophtha.2012.09.006
pubmed: 23084240
Martin DF, Ying G, Grunwald JE, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908. https://doi.org/10.1056/NEJMOA1102673/SUPPL_FILE/NEJMOA1102673_DISCLOSURES.PDF .
doi: 10.1056/NEJMOA1102673/SUPPL_FILE/NEJMOA1102673_DISCLOSURES.PDF
pubmed: 21526923
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31. https://doi.org/10.1056/NEJMoa054481 .
doi: 10.1056/NEJMoa054481
pubmed: 17021318
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44. https://doi.org/10.1056/NEJMoa062655 .
doi: 10.1056/NEJMoa062655
pubmed: 17021319
Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98. https://doi.org/10.1016/j.ophtha.2012.03.053 .
doi: 10.1016/j.ophtha.2012.03.053
pubmed: 22555112
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411. https://doi.org/10.1016/j.ophtha.2012.04.015 .
doi: 10.1016/j.ophtha.2012.04.015
pubmed: 22578446
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382:1258–67. https://doi.org/10.1016/S0140-6736(13)61501-9 .
doi: 10.1016/S0140-6736(13)61501-9
pubmed: 23870813
Ho AC, Busbee BG, Regillo CD, Heier JS, Lindstrom RL, Orr SC, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121:2181–92. https://doi.org/10.1016/J.OPHTHA.2014.05.009 .
doi: 10.1016/J.OPHTHA.2014.05.009
pubmed: 25015215
Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046–56. https://doi.org/10.1016/J.OPHTHA.2012.10.014 .
doi: 10.1016/J.OPHTHA.2012.10.014
pubmed: 23352196
Bressler NM, Doan QV, Varma R, Lee PP, Suñer IJ, Dolan C, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol (Chic, Ill 1960). 2011;129:709–17. https://doi.org/10.1001/ARCHOPHTHALMOL.2011.140 .
doi: 10.1001/ARCHOPHTHALMOL.2011.140
Zarranz-Ventura J, Parrado-Carrillo A, Nguyen V, Sararols L, Garay-Aramburu G, Puzo M, et al. Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes. Clin Exp Ophthalmol. 2022;50:312–24. https://doi.org/10.1111/CEO.14054 .
doi: 10.1111/CEO.14054
pubmed: 35106882
Ozawa Y, Veritti D, Sarao V, Soppelsa V, Danese C, Chhablani J, et al. Clinical medicine managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression. J Clin Med. 2022. https://doi.org/10.3390/jcm11020325 .
Martin-Pinardel R, Izquierdo-Serra J, De Zanet S, Parrado-Carrillo A, Garay-Aramburu G, Puzo M, et al. Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database. Br J Ophthalmol. 2024;108:253–62. https://doi.org/10.1136/bjo-2022-322297 .
doi: 10.1136/bjo-2022-322297
pubmed: 36627173
Recommendations | Age-related macular degeneration | Guidance | NICE.
Yeung L, Hsieh YT, Yang CH, Chen LJ, Chen SJ, Cheng CK, et al. Management of neovascular age-related macular degeneration: Taiwan expert consensus. J Formos Med Assoc. 2021;120:2061–71. https://doi.org/10.1016/J.JFMA.2021.06.012 .
doi: 10.1016/J.JFMA.2021.06.012
pubmed: 34274193
Gillies MC, Walton R, Liong J, Arnold JJ, McAllister I, Moriet N, et al. Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! project. Retina. 2014;34:188–95. https://doi.org/10.1097/IAE.0b013e318296b271 .
doi: 10.1097/IAE.0b013e318296b271
pubmed: 23836194
Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247:137–42. https://doi.org/10.1007/s00417-008-0926-0 .
doi: 10.1007/s00417-008-0926-0
pubmed: 18766368
Shona O, Gupta B, Vemala R, Sivaprasad S. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision. Clin Exp Ophthalmol. 2011;39:5–8. https://doi.org/10.1111/J.1442-9071.2010.02424.X .
doi: 10.1111/J.1442-9071.2010.02424.X
pubmed: 21040311
Rahimy E, Rayess N, Ho AC, Regillo CD. Treatment outcomes for neovascular age-related macular degeneration patients with initial vision better than 20/40 using a treat-and-extend regimen. Retina. 2016;36:875–80. https://doi.org/10.1097/IAE.0000000000000814 .
doi: 10.1097/IAE.0000000000000814
pubmed: 26630316
Langelaan M, De Boer MR, Van Nispen RMA, Wouters B, Moll AC, Van Rens GHMB. Impact of visual impairment on quality of life: a comparison with quality of life in the general population and with other chronic conditions. Ophthalmic Epidemiol. 2007;14:119–26. https://doi.org/10.1080/09286580601139212 .
doi: 10.1080/09286580601139212
pubmed: 17613846
Fenwick EK, Ong PG, Man REK, Cheng CY, Sabanayagam C, Wong TY, et al. Association of Vision Impairment and Major Eye Diseases With Mobility and Independence in a Chinese Population. JAMA Ophthalmol. 2016;134:1087–93. https://doi.org/10.1001/JAMAOPHTHALMOL.2016.2394 .
doi: 10.1001/JAMAOPHTHALMOL.2016.2394
pubmed: 27467140
Veritti D, Sarao V, Soppelsa V, Danese C, Chhablani J, Lanzetta P. Managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression. J Clin Med. 2022;11. https://doi.org/10.3390/JCM11020325 .
Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:1837–45. https://doi.org/10.1016/j.ophtha.2015.05.010 .
doi: 10.1016/j.ophtha.2015.05.010
pubmed: 26096346
Tufail A. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity manuscript no. 2013-568. Ophthalmology. 2014;121:1092–101. https://doi.org/10.1016/j.ophtha.2013.11.031 .
doi: 10.1016/j.ophtha.2013.11.031
Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T, McKibbin M, et al. The neovascular age-related macular degeneration database: Report 2: Incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 2014;121:1966–75. https://doi.org/10.1016/j.ophtha.2014.04.026 .
doi: 10.1016/j.ophtha.2014.04.026
pubmed: 24953791
Izquierdo-Serra J, Martin-Pinardel R, Moll-Udina A, Bernal-Morales C, Garay-Aramburu G, Sanchez-Monroy J, et al. Macular neovascularization type influence on anti-VEGF intravitreal therapy outcomes in age-related macular degeneration. Ophthalmol Retin. 2024;8:350–9. https://doi.org/10.1016/j.oret.2023.10.022 .
doi: 10.1016/j.oret.2023.10.022